2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the Prolaris genetic test in predicting prostate cancer aggressiveness in African-American men.
According to Brawer, African Americans have the highest rate of prostate cancer in the world and tend to present with more aggressive cancer.
The Prolaris test is done on the diagnostic biopsy and has been shown to provide a much more precise risk assessment as to the risk of biochemical recurrence, the development of metastases, or disease-specific mortality. This test has been shown to work across all risk groups, explains Brawer.
Related Content: